A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Date publication

avril 2018

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre

Tous les auteurs :
Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29475724

Résumé

Patients with follicular lymphoma have heterogeneous outcomes. Predictor models to distinguish, at diagnosis, between patients at high and low risk of progression are needed. The objective of this study was to use gene-expression profiling data to build and validate a predictive model of outcome for patients treated in the rituximab era.

Mots clés

Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Clinical Trials, Phase III as Topic, Female, Gene Expression Profiling, Humans, Internationality, Lymphoma, Follicular, drug therapy, Maintenance Chemotherapy, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Predictive Value of Tests, Progression-Free Survival, Proportional Hazards Models, RNA, Neoplasm, analysis, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Assessment, methods, Rituximab, administration & dosage

Référence

Lancet Oncol.. 2018 Apr;19(4):549-561